Targeted drugs ramp up cancer mutability

Mutagenesis can drive carcinogenesis and continue during cancer progression, generating genetic intratumor heterogeneity that enables cancer adaptation through Darwinian evolution ([ 1 ][1]). Analyses, such as mutational signature characterization, have revealed specific mutational processes and their temporal activity during carcinogenesis and tumor progression ([ 2 ][2]). Nevertheless, many of…

Read the full article here

Source: Science

Categories: Hem/Oncs

Tags: cancer

Tweets with this article

Aditya Bardia, MD

RT @EricTopol: When drugs for #cancer induce mutations that promote resistance to therapy https://t.co/bvf3hh5xYb by @MarcoGerlinger @ICR_L…

Antibody Drug Conjugate Sacituzumab Govitecan Enables A Sequential TOP1/PARP Inhibitor Cancer Therapy Strategy in Breast Cancer Patients

Abstract. Purpose: The Antibody-Drug Conjugate (ADC) Sacituzumab govitecan (SG) comprises the topoisomerase 1 (TOP1) inhibitor SN-38, coupled to a monoclonal antibody targeting trophoblast cell surface…

Aditya Bardia, MD May 29, 2024

TROPION-Breast03: a randomized phase III global trial of datopotamab deruxtecan ± durvalumab in patients with triple-negative breast cancer and residual invasive disease at surgical resection after neoadjuvant therapy – Aditya Bardia, Lajos Pusztai, Kathy Albain, Eva Maria Ciruelos, Seock-Ah Im, Daw

Background: Despite advances in the treatment of early triple-negative breast cancer (TNBC), patients with residual invasive disease after neoadjuvant therapy h…

Aditya Bardia, MD May 2, 2024

Enhertu demonstrated statistically significant and clinically meaningful improvement in progression-free survival in HR-positive, HER2-low metastatic breast cancer following one or more lines of endocrine therapy in DESTINY-Breast06 Phase III trial

Positive high-level results from the DESTINY-Breast06 Phase III trial showed that Enhertu (trastuzumab deruxtecan) demonstrated a statistically significant and clinically meaningful improvement in progression-free survival…

Aditya Bardia, MD April 30, 2024

Enhertu demonstrated statistically significant and clinically meaningful improvement in progression-free survival in HR-positive, HER2-low metastatic breast cancer following one or more lines of endocrine therapy in DESTINY-Breast06 Phase III trial

Aditya Bardia, MD April 29, 2024

Enhertu demonstrated statistically significant and clinically meaningful improvement in progression-free survival in HR-positive, HER2-low metastatic breast cancer following one or more lines of endocrine therapy in DESTINY-Breast06 Phase III trial

Aditya Bardia, MD April 29, 2024

Enhertu demonstrated statistically significant and clinically meaningful improvement in progression-free survival in HR-positive, HER2-low metastatic breast cancer following one or more lines of endocrine therapy in DESTINY-Breast06 Phase III trial

Aditya Bardia, MD April 29, 2024

A Study of Dato-DXd With or Without Durvalumab Versus Investigator’s Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03) – Full Text View – ClinicalTrials.gov

A Study of Dato-DXd With or Without Durvalumab Versus Investigator’s Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response…

Aditya Bardia, MD April 24, 2024

Related Articles